AstraZeneca (NASDAQ:AZN), Sanofi (NASDAQ:SNY) and Swedish Orphan Biovitrum (Sobi) (OTCPK:BIOVF) updated their contracts related to developing and commercializing respiratory syncytial virus (RSV) ...
ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...
Sanofi will cut insulin prices by 70% or more and cap out-of-pocket costs at $35 for people with commercial insurance Sanofi follows Eli Lilly and Novo Nordisk in announcing insulin price cuts.
Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd ("Vicebio") ( ...
Sanofi will continue to provide different programs to ensure access and affordability to patients depending on their coverage situations and will continue to monitor policy and market changes. Our ...
Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema ...
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results